istock-182687703-1-
stevenallan / iStockphoto.com
13 March 2018Europe

Pay-for-delay settlements remain steady in EU

The number of ‘pay-for-delay’ patent settlements in the EU has “stabilised at a low level”, according to the European Commission.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
6 November 2017   Pharmaceutical companies have entered into fewer potential ‘pay-for-delay’ patent settlements for the second year in a row, following the US Supreme Court’s decision in FTC v Actavis.
Europe
15 March 2018   Israeli pharmaceutical company Teva “robustly” responded to the European Commission’s charge of anti-competitive behaviour at a hearing earlier this week.

More on this story

Americas
6 November 2017   Pharmaceutical companies have entered into fewer potential ‘pay-for-delay’ patent settlements for the second year in a row, following the US Supreme Court’s decision in FTC v Actavis.
Europe
15 March 2018   Israeli pharmaceutical company Teva “robustly” responded to the European Commission’s charge of anti-competitive behaviour at a hearing earlier this week.

More on this story

Americas
6 November 2017   Pharmaceutical companies have entered into fewer potential ‘pay-for-delay’ patent settlements for the second year in a row, following the US Supreme Court’s decision in FTC v Actavis.
Europe
15 March 2018   Israeli pharmaceutical company Teva “robustly” responded to the European Commission’s charge of anti-competitive behaviour at a hearing earlier this week.